MONTREAL, Dec. 5 /PRNewswire-FirstCall/ - Procyon Biopharma Inc. , a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced today that it will be hosting a conference call and webcast to explain PSP94 diagnostic marker study findings - as previously announced Friday, December 2, 2005 - showing that PSP94 serum levels were a better predictor of the aggressivity of the cancer than PSA (Prostate Specific Antigen) or FTPSA (Free to Total PSA ratio) on Tuesday, December 6th at 9:00 AM ET.
Hans J. Mader, president and chief executive officer of Procyon Biopharma, Dr. Chandra Panchal, senior vice-president of new technologies of Procyon Biopharma, Dr. Daniel Bock, vice-president, business development and licensing of Procyon Biopharma as well as Dr. Robert K. Nam, MD, FRCSC, Assistant Professor of Surgery, Division of Urology at the Sunnybrook and Women’s College Health Sciences Centre, University of Toronto and Dr. Phil Gold, C.C., O.Q., M.D., Ph.D., Executive Director, Clinical Research Center, Professor of Medicine, Physiology and Oncology, McGill University, The Montreal General Hospital, will be on the call to discuss implications of PSP94 diagnostic marker study findings.
Interested parties may access the conference call by way of telephone or webcast. The webcast will be available at www.procyonbiopharma.com and archived for 90 days for replay purposes. The numbers to access the conference call are (416) 644-3414 (U.S. and Canada) and 1(800) 814-4853 (international).
A replay of the call will be available from December 6, 2005 to March 6, 2006 and the numbers to access the replay are (416) 640-1917 (U.S. and Canada) and 1(877) 289-8525 (international) with access code 21167009(pound key).
ABOUT PSP94
PSP94 is one of the three major proteins secreted in the seminal fluid, together with PSA and Prostatic Acid Phosphatase (PAP). PSP94-based test kits measure the amount of free PSP94, bound PSP94 and PSP94 binding protein present in the blood, the relative ratios of which are believed to have utility in prostate cancer prognosis, diagnosis and monitoring. These test kits differentiate between patients with prostate cancer and patients with benign conditions among patients who underwent a biopsy for prostate cancer. The PSP94-based test kits have the potential to significantly reduce the number of first and repeat prostate biopsies thus reducing the associated cost, morbidity and infection risk. Recent studies also indicate that the PSP94-based test kits were able to predict patients suffering from a more aggressive disease. PSP94 was found to be a strong predictor of relapse post- radiotherapy as well as following radical prostatectomy.
ABOUT PROCYON BIOPHARMA INC.
Procyon Biopharma Inc. is a biotechnology company actively engaged in the discovery and development of innovative therapeutics in the fields of cancer and HIV/AIDS. The Company leverages its strengths in research and clinical development, bringing products through late-stage clinical trials and then evaluating the best options for further development, such as co-development and licensing. Procyon’s pipeline includes: PCK3145, a non-toxic peptide soon to enter a Phase II North American trial for the treatment of advanced metastatic prostate cancer; TVT-Dox, a tumor vasculature targeting technology for the treatment of solid tumors for which an IND filing is expected within 12 months; and, PPL-100, a protease inhibitor for the treatment of drug- resistant HIV/AIDS soon to enter the clinic. Procyon has won the 2005 Frost & Sullivan Award for Excellence in Technology for its overall scientific and technological contributions towards the advancement of cancer therapy. Headquartered in Montreal, Procyon shares are listed on the Toronto Stock Exchange (TSX) under the ticker symbol PBP. For more information, visit www.procyonbiopharma.com.
This release contains forward-looking statements that reflect the company’s current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company’s filings.
PROCYON BIOPHARMA INC.
CONTACT: Procyon Biopharma Inc.: Julie M. Thibodeau, Director,Communications, jthibodeau@procyonbiopharma.com, ir@procyonbiopharma.com,(514) 685-2000 ext 118